A prospective, multicenter, randomized controlled clinical trial with open-label treatment and blinded endpoint assessment.
Age 18-75 years.
Previously unruptured saccular cerebral aneurysm arising from intradural segments of the internal carotid artery and intracranial segments of the vertebral artery.
Measuring ≤10mm in maximum diameter
Subjects capable of understanding the study's purpose, willing to participate, and have signed an informed consent form.
Subjects with two or more multiple aneurysms requiring treatment within one year.
Subjects with arteriovenous malformations or moyamoya disease.
Subjects with ruptured, recurrent, or dissecting aneurysms.
Subjects with symptomatic cerebral stenosis >70%;